FloShield laparoscopic vision system producer and distributor Minimally Invasive Devices announced Monday that it has acquired $2.5 million in additional Series B funding. The fund totals to $11.5 million, after an initial $9 million financing spearheaded by original investor Charter Life Sciences. Canaan Partners is the company's newest investor.
Minimally Invasive Devices' flagship device is FloShield. The product is currently the only device in the world that can maintain a clear field of vision throughout an entire laparoscopic surgery. The technology is currently being utilized with high-definition vision systems which prevents interruptions due to loss of vision during operations. Loss of vision during this critical procedure may lead to problems such as delay and surgeon frustration.
"Currently, surgeons will lose vision and need to stop surgery to clean the lens externally as often as ten times per hour," said Minimally Invasive Devices Chief Executive Officer and founder Wayne Poll, M.D.
"We believe that surgeons will appreciate and value the benefits of a consistently clear view and will come to expect this as a standard, without nostalgia for the days they needed to clean the lens constantly when vision was lost."FloShield laparoscopic vision system producer and distributor Minimally Invasive Devices announced Monday that it has acquired $2.5 million in additional Series B funding. The fund totals to $11.5 million, after an initial $9 million financing spearheaded by original investor Charter Life Sciences. Canaan Partners is the company's newest investor.
Minimally Invasive Devices' flagship device is FloShield. The product is currently the only device in the world that can maintain a clear field of vision throughout an entire laparoscopic surgery. The technology is currently being utilized with high-definition vision systems which prevents interruptions due to loss of vision during operations. Loss of vision during this critical procedure may lead to problems such as delay and surgeon frustration.
"Currently, surgeons will lose vision and need to stop surgery to clean the lens externally as often as ten times per hour," said Minimally Invasive Devices Chief Executive Officer and founder Wayne Poll, M.D.
"We believe that surgeons will appreciate and value the benefits of a consistently clear view and will come to expect this as a standard, without nostalgia for the days they needed to clean the lens constantly when vision was lost."
Join the Conversation